Clinical trial · Observational
Ovarian Tumor Biopsies to Study Response to Treatments
Paired Biopsies to Develop a Cellular Signature
NCT02952521CI-TRIAL-00058388completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a research study to look at differences in tumor tissue from ovarian cancer patients that may help to determine response and resistance to treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Draw | Procedure | — | UNRESOLVED |
| Tumor Tissue Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Epithelial ovarian cancer
- description
- * Whole blood sample collection * Up to 3 fresh tumor tissue core biopsies * Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)
- interventionNames
- Procedure: Blood Draw
- Procedure: Tumor Tissue Biopsy
Primary outcomes (2)
- measure
- Pearson correlation for changes between kinome and CA125
- timeFrame
- 5 years
- measure
- Paired T-test for differences in kinome between responders and non-responders
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years. * Histological diagnosis of epithelial ovarian cancer * Eastern Cooperative Oncology Group (ECOG) performance status ≤2. * Life expectancy of greater than 3 months * Diagnosis of epithelial ovarian cancer undergoing chemotherapy as part of standard care or a clinical trial OR receiving a targeted therapy with a targeted agent * Must be agreeable to paired biopsies * Must have disease amenable to paired biopsy. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Any contraindication to biopsy * Need for anticoagulation that cannot be interrupted
References
Publications (0)
Data not yet available
No reference posted for this study.